| 2022 MEDICAL ONCOLOGY MEASURES | VRB MEASURE |
|---|---|
| Chemotherapy intent (curative vs non-curative) documented before or within 2 weeks after administration | |
| NK1 receptor antagonist and olanzapine prescribed or administered with high emetic risk chemotherapy | X |
| NK1 receptor antagonist for low or moderate emetic risk cycle 1 chemotherapy (lower is better) | X |
| Complete family history documented for patients with invasive cancer | |
| GCSF administered to patients who received chemotherapy for non-curative intent (lower is better) | |
| Hospice enrollment | X |
| Hospice enrollment within 7 days of death (lower is better) | X |
| Completeness of race and ethnicity data | X |
| Tobacco cessation counseling administered or patient referred in past year | X |
| Smoking status recorded in medical record | X |
| Smoking treatment recorded in medical record | X |
| 2022 GYNECOLOGIC ONCOLOGY MEASURES | VRB MEASURE |
|---|---|
| Days from debulking surgery to chemotherapy start | X |
| Outpatient prescribing of opioids for cancer patients after laparoscopic or open hysterectomy | X |